The global helicobacter pylori diagnostics market size is projected to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the improved cost-effectiveness of diagnosis of infection and rising demand for personalized antibiotic therapy.
Helicobacter pylori, also known as an aerobic gram-negative bacteria, is commonly found in stomach. Although stomach ecology is balanced by this bacteria, still it can cause infection to the inner stomach lining. The bacteria acts as a causative agent for gastric ulcers, gastritis, stomach cancer, infection in the small intestine, and duodenal ulcers. This generates demand for diagnostic methods for helicobacter pylori infection. In case of positive diagnosis of ulcers, antibiotic treatment is generally given to patients for 10 to 14 days.
In 1994, the International Agency for Research on Cancer categorized helicobacter pylori as a carcinogen. Although the exact mode of transmission of this infection remains uncertain, it is suggested that the infection can be transmitted from one person to other through fecal-oral route. The helicobacter pylori infection, which is mostly seen in childhood has no any specific symptoms. This infection is highly prevalent in developing nations due to some major factors such as dense population, lack of water supply, poor personal hygiene, and poor sanitation.
Market Trends, Drivers, Restraints, and Opportunities
- Rising awareness about the infection and growing governments’ programs for the healthcare development especially in developing countries are key factors responsible for driving market growth.
- Availability of personalized antibiotic treatment, affordable, and cost-effective diagnosis are drivers for the helicobacter pylori diagnostics market.
- Rapid development of advanced technology for diagnostics and rising preference for early detection of the infection are major factors boosting the market growth.
- Easy accessibility of point-of-care testing as well as availability of several invasive and non-invasive devices are anticipated to propel the growth of the market.
- Lack of awareness about benefits of the testing and unavailability of skilled professionals are projected to hamper the market growth.
Scope of the Report
The report on the global helicobacter pylori diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Helicobacter Pylori Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Technology (Immunoassays, POC, and Molecular Diagnostics) and End-users (Hospitals, Diagnostics Laboratories, and Clinics)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Thermo Fisher Scientific; Biohit; Quest Diagnostics; Meridian Bioscience; Bio-Rad Laboratories; Alpha Laboratories; F. Hoffmann-La Roche; Coris BioConcept; Certest Biotec; and Epitope Diagnostics
|
Helicobacter Pylori Diagnostics Market Segment Insights
Immunoassay segment to account for a key share
Based on technology, the global helicobacter pylori diagnostics market is divided into immunoassays, POC, and molecular diagnostics. The immunoassay segment accounted for a large market share in 2019 and is projected to expand at a rapid growth rate during the forecast period. For detecting of antibodies, many technologies are used and the enzyme immunoassays is one of the most widely adopted technology for the same purpose. On the other hand, the POC segment is expected to register substantial growth during the forecast period owing to wide adoption of the technique for helicobacter pylori diagnostics. Meanwhile, the molecular diagnostics accounted for the second largest market share in 2019 due to its high accuracy and improved testing result.
Hospitals segment to hold a major market share
On the basis of end-users, the market is divided into hospitals, diagnostics laboratories, and clinics. In 2019, the hospitals segment held a major market share and the trend is likely to continue during the forecast period. The segment growth can be attributed to ease of accessibility of doctors and medical staffs who are expert in disease presentation of related diseases such as gastritis, infections to small intestine, duodenal ulcers, gastric ulcers, and stomach cancer.
The diagnostic laboratories segment, however, is anticipated to show a fast CAGR during the forecast period owing to efficient and specialized detection of infection in the specialized laboratories. Moreover, the rising adoption of the testing process of the infection in diagnostic laboratories in a search of finding advanced drugs and techniques for the treatment present another key driver for the segment growth. In 2019, the combined share of hospitals and diagnostics laboratories represented more than 80% share of the total market.
North America is projected to exhibit a robust CAGR
In terms of regions, the global helicobacter pylori diagnostics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America dominated the market in 2019 and is projected to exhibit a robust CAGR during the forecast period owing to better economy and healthcare infrastructural development. Moreover, the presence of key global players in the region especially in the US is another crucial factor for the regional market expansion. On the other hand, the market in Asia Pacific is anticipated to register a fast CAGR during the forecast period owing to increasing rate of population growth and rising occurrence of helicobacter pylori infections in the region.
Segments
Segments Covered in the Report
The global helicobacter pylori diagnostics market has been segmented on the basis of
Technology
- Immunoassays
- POC
- Molecular Diagnostics
End-users
- Hospitals
- Diagnostics Laboratories
- Clinics
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Thermo Fisher Scientific
- Biohit, Quest Diagnostics
- Meridian Bioscience
- Bio-Rad Laboratories
- Alpha Laboratories
- F. Hoffmann-La Roche
- Coris BioConcept
- Certest Biotec
- Epitope Diagnostics
Competitive Landscape
Some of the key players competing in the market are Thermo Fisher Scientific, Biohit, Quest Diagnostics, Meridian Bioscience, Bio-Rad Laboratories, Alpha Laboratories, F. Hoffmann-La Roche, Coris BioConcept, Certest Biotec, and Epitope Diagnostics.
These three major players such as Bio-Rad Laboratories, Quest Diagnostics, and Thermo Fisher Scientific accounted for a highest share of market in 2019 owing to wider geographical presence and broad product portfolio. The key players are constantly adopting many strategies such as mergers and acquisitions, regional expansions, strategic partnerships, and new product development to expand their market positions.
Request For Customization
Enquiry Before Buying
Speak With Analyst
